FMR1NB

Across TCGA pan-cancer cohorts, FMR1NB Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FMR1NB data layer compared with 22 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FMR1NB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FMR1NB expression acts as an unfavorable survival marker.

BRCA, ESCA, and LUSC are the cancer types where FMR1NB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.715	0.963	<.001	20	view →
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
LUSC	DFS	Median	II,III,IV	0.155	0.760	<.001	12	view →
LIHC	OS	Median	All	0.152	0.688	.017	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
HNSC	OS	Median	All	0.179	0.685	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FMR1NB–BRCA (OS)

Open the BRCA breakdown →